Financials in USD. Standardized financial statements.
A compact view of how bioAffinity Technologies, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $6.16M | $9.36M | $2.53M | $4,803 | $0 | $0 | $0 |
| Revenue Growth? | -34.2% | +269.7% | +52617.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $4.73M | $5.98M | $1.74M | $467 | $4,817 | $22,242 | $40,278 |
| Gross Profit? | $1.43M | $3.38M | $791,615 | $4,336 | -$4,817 | -$22,242 | -$40,278 |
| Gross Margin? | +23.2% | +36.1% | +31.3% | +90.3% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $12.00M | $12.33M | $8.77M | $4.02M | $2.20M | $2.58M | $3.05M |
| Operating Income? | -$10.57M | -$8.95M | -$7.97M | -$4.01M | -$2.21M | -$2.60M | -$3.09M |
| EBITDA? | -$10.07M | -$8.33M | -$7.63M | -$5.61M | -$5.32M | -$6.86M | -$3.05M |
| Income Before Tax | -$14.87M | -$9.03M | -$7.92M | -$8.15M | -$6.32M | -$7.27M | -$3.30M |
| Income Tax Expense | $44,042 | $11,650 | $20,993 | $2,459 | $1,950 | $2,750 | $3,200 |
| Net Income? | -$14.91M | -$9.04M | -$7.94M | -$8.15M | -$6.33M | -$7.27M | -$3.31M |
| EPS? | $-8.66 | $-22.50 | $-27.30 | $-54.30 | $-70.86 | $-29.70 | $-13.50 |
| Diluted EPS? | $-8.66 | $-22.50 | $-27.30 | $-54.30 | $-69.57 | $-29.70 | $-13.50 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality